Glenmark launches generic Accuhaler in Denmark

Glenmark Pharmaceuticals launches its first inhaled respiratory product in Europe. The company has marketing and distribution right for the product in Europe.

Glenmark's European arm announced the launch of a generic version of Seretide Accuhaler in Denmark after receiving regulatory approval for its generic inhaler. The company has market authorizations for the generic product in Finland, Iceland, Norway and Sweden.

The company has developed the product through a strategic development and licensing agreement with Celon Pharma S.A. Seretide Accuhaler is GlaxoSmithKline’s product, wherein Seretide is available as a dry powder device branded as Accuhaler. The active ingredients are Fluticasone propionate, Salmeterol xinafoate used for the treatment of asthma and COPD.

Glenmark Pharmaceuticals Limited (GPL) is a company operating in the pharma space with a diverse pipeline in the oncology, respiratory disease and dermatology segment.

Meanwhile, at 10:41 hours, the stock of Glenmark was trading at Rs. 509.60 per share, up by 0.66 per cent, on Wednesday.